T1	DISO 140 159	Artritis Psoriásica
#1	AnnotatorNotes T1	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T2	PROC 189 274	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de fase III
T3	PROC 325 346	demostrar la eficacia
#2	AnnotatorNotes T3	C1707887; Efficacy Study; Research Activity
T4	CHEM 278 289	secukinumab
#3	AnnotatorNotes T4	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	PROC 371 417	evaluar la seguridad, tolerabilidad y eficacia
T6	DISO 462 481	Artritis Psoriásica
#4	AnnotatorNotes T6	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T7	DISO 512 531	Artritis Psoriásica
#5	AnnotatorNotes T7	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T8	PROC 560 571	Diagnóstico
#6	AnnotatorNotes T8	C0011900; Diagnosis; Diagnostic Procedure
T9	DISO 624 632	síntomas
#7	AnnotatorNotes T9	C1457887; Symptoms; Sign or Symptom
T10	DISO 575 578	APs
#8	AnnotatorNotes T10	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T11	PROC 708 728	anticuerpos anti-CCP
#9	AnnotatorNotes T11	C1318660; Anti-cyclic citrullinated peptide antibody level; Laboratory Procedure
T12	PROC 758 769	Diagnóstico
#10	AnnotatorNotes T12	C0011900; Diagnosis; Diagnostic Procedure
T13	DISO 773 792	psoriasis en placas
#11	AnnotatorNotes T13	C0263361; Psoriasis vulgaris; Disease or Syndrome
T14	DISO 843 852	psoriasis
#12	AnnotatorNotes T14	C0033860; Psoriasis; Disease or Syndrome
T15	PROC 867 890	control de los sintomas
T16	CHEM 895 900	AINES
#13	AnnotatorNotes T16	C0003211; Anti-Inflammatory Agents, Non-Steroidal; Pharmacologic Substance
T17	PROC 942 951	protocolo
#14	AnnotatorNotes T17	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T18	PROC 980 1000	Radiografía de tórax
#15	AnnotatorNotes T18	C0039985; Plain chest X-ray; Diagnostic Procedure
T19	PROC 1003 1014	RM de tórax
T20	ANAT 1009 1014	tórax
#16	AnnotatorNotes T20	C0817096; Chest; Body Location or Region | C1269614; Entire thorax; Body Part, Organ, or Organ Component
T21	DISO 1032 1060	proceso infeccioso o maligno
T22	CHEM 1093 1113	analgésicos opioides
#17	AnnotatorNotes T22	C0002772; Analgesics, Opioid; Organic Chemical · Pharmacologic Substance
T23	CHEM 1153 1164	secukinumab
#18	AnnotatorNotes T23	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	CHEM 1174 1191	fármaco biológico
#19	AnnotatorNotes T24	C0005515; Biological Factors; Biologically Active Substance (?)
T25	CHEM 1235 1252	receptor de IL-17
T26	PROC 1271 1283	tratamientos
#20	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	CHEM 1286 1298	medicaciones
#21	AnnotatorNotes T27	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T28	PROC 1318 1329	tratamiento
#22	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	DISO 1336 1345	psoriasis
#23	AnnotatorNotes T29	C0033860; Psoriasis; Disease or Syndrome
T30	CHEM 1449 1453	TNFα
T31	PROC 1487 1498	Tratamiento
#24	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	PROC 1520 1548	terapia de depleción celular
T33	ANAT 1541 1548	celular
#25	AnnotatorNotes T33	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T34	PROC 1589 1598	protocolo
#26	AnnotatorNotes T34	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T35	DISO 662 665	APs
#27	AnnotatorNotes T35	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T36	PROC 688 705	Factor reumatoide
#28	AnnotatorNotes T36	C0201660; Rheumatoid Factor Measurement; Laboratory Procedure
T37	ANAT 817 821	uñas
#29	AnnotatorNotes T37	C0027342; Nail plate; Body Part, Organ, or Organ Component
T38	ANAT 995 1000	tórax
#30	AnnotatorNotes T38	C0817096; Chest; Body Location or Region | C1269614; Entire thorax; Body Part, Organ, or Organ Component
T39	DISO 882 890	sintomas
#31	AnnotatorNotes T39	C1457887; Symptoms; Sign or Symptom
T40	CHEM 1224 1229	IL-17
T41	CHEM 1389 1406	inmunomoduladores
#32	AnnotatorNotes T41	C1527392; Immunomodulators; Immunologic Factor · Pharmacologic Substance
T42	Date 13 17	2013
T43	Duration 57 71	las 24 semanas
T44	Duration 116 122	3 años
T45	LIVB 126 135	pacientes
#33	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T46	Route 290 300	subcutáneo
T47	Duration 349 363	las 24 semanas
T48	Date 418 431	a largo plazo
T49	Duration 438 444	3 años
T50	LIVB 448 457	pacientes
#34	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Duration 641 657	al menos 6 meses
T54	Date 1061 1069	en curso
T55	LIVB 1073 1082	Pacientes
#35	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T56	Date 1261 1267	actual
T57	LIVB 1349 1358	Pacientes
#36	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T62	DEVI 304 318	autoinyectores
A1	Status T23 History_of
A2	Status T24 History_of
A3	Assertion T27 Contraindicated
A4	Assertion T26 Contraindicated
A5	Status T41 History_of
A6	Status T31 History_of
A7	Status T32 History_of
#37	AnnotatorNotes T2	C0282461; Phase 3 Clinical Trials; Research Activity + C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#38	AnnotatorNotes T46	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
#39	AnnotatorNotes T48	C0443252; Long-term; Temporal Concept
#40	AnnotatorNotes T56	C0521116; Current (present time); Temporal Concept 
#41	AnnotatorNotes T5	C0511730; Identify product efficacy and safety issues; Health Care Activity + C3274448; Tolerability Study; Research Activity
#42	AnnotatorNotes T30	C1456820; Tumor Necrosis Factor-alpha; Amino Acid, Peptide, or Protein · Immunologic Factor
#43	AnnotatorNotes T40	C0384648; Interleukin-17; Amino Acid, Peptide, or Protein · Immunologic Factor 
#44	AnnotatorNotes T25	C1721056; Receptors, Interleukin-17; Amino Acid, Peptide, or Protein · Receptor
#45	AnnotatorNotes T62	C1553477; AutoInjector; Medical Device 
#46	AnnotatorNotes T15	C1274136; Symptom control (regime/therapy); Therapeutic or Preventive Procedure
#47	AnnotatorNotes T54	C0521116; Current (present time); Temporal Concept 
R1	Experiences Arg1:T45 Arg2:T1	
R2	Has_Route_or_Mode Arg1:T4 Arg2:T46	
R3	Used_for Arg1:T62 Arg2:T4	
R4	After Arg1:T3 Arg2:T47	
R5	Overlap Arg1:T5 Arg2:T48	
R6	Has_Duration_or_Interval Arg1:T5 Arg2:T49	
R7	Experiences Arg1:T50 Arg2:T4	
R8	Experiences Arg1:T50 Arg2:T6	
T52	Quantifier_or_Qualifier 160 166	activa
#48	AnnotatorNotes T52	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R9	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T52	
T53	Quantifier_or_Qualifier 482 488	activa
#49	AnnotatorNotes T53	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R10	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T53	
T58	Quantifier_or_Qualifier 793 799	activa
#50	AnnotatorNotes T58	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R11	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T58	
T59	Quantifier_or_Qualifier 669 685	moderada a grave
#51	AnnotatorNotes T59	C1299393; Moderate to severe; Qualitative Concept
R12	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T59	
T60	CONC 601 617	criterios CASPAR
R13	Used_for Arg1:T60 Arg2:T8	
R14	Causes Arg1:T10 Arg2:T9	
R15	Has_Duration_or_Interval Arg1:T9 Arg2:T51	
R16	Causes Arg1:T35 Arg2:T9	
T61	PROC 745 754	selección
#52	AnnotatorNotes T61	C0242802; Patient Selection; Research Activity
R17	Overlap Arg1:T11 Arg2:T61	
R18	Overlap Arg1:T36 Arg2:T61	
T63	Result_or_Value 729 738	negativos
#53	AnnotatorNotes T63	C0205160; Negative; Finding
R19	Has_Result_or_Value Arg1:T36 Arg2:T63	
R20	Has_Result_or_Value Arg1:T11 Arg2:T63	
T64	Observation 802 821	cambios en las uñas
#54	AnnotatorNotes T64	C0234909; Nail changes; Finding
R21	Location_of Arg1:T37 Arg2:T64	
R22	Overlap Arg1:T64 Arg2:T14	
R24	Used_for Arg1:T16 Arg2:T15	
T65	Observation 856 890	Inadecuado control de los sintomas
R25	Location_of Arg1:T38 Arg2:T18	
R26	Location_of Arg1:T20 Arg2:T19	
#55	AnnotatorNotes T19	C0202826; Magnetic Resonance Imaging (MRI) of Chest; Diagnostic Procedure
R27	Overlap Arg1:T21 Arg2:T54	
#56	AnnotatorNotes T21	C0745283; INFECTIOUS PROCESS; Pathologic Function | C4740599; Active malignant condition; Finding (?)
R30	Experiences Arg1:T55 Arg2:T22	
T66	Quantifier_or_Qualifier 1114 1130	de alta potencia
R31	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T66	
T67	Quantifier_or_Qualifier 1192 1252	que se dirija directamente a la IL-17 o al receptor de IL-17
R32	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T67	
A8	Status T67 History_of
R33	Overlap Arg1:T26 Arg2:T56	
R34	Overlap Arg1:T27 Arg2:T56	
R35	Experiences Arg1:T57 Arg2:T41	
T68	Quantifier_or_Qualifier 1407 1417	biológicos
#57	AnnotatorNotes T68	C0205460; biological; Qualitative Concept
A9	Status T68 History_of
R36	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T68	
#58	AnnotatorNotes T65	C2712003; Lack of symptom control; Finding
#59	AnnotatorNotes T32	C1171324; B-cell depletion; Therapeutic or Preventive Procedure
A10	Experiencer T45 Patient
A11	Experiencer T50 Patient
A12	Experiencer T55 Patient
A13	Experiencer T57 Patient
